Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε , VEGFR2, MAP4K5, MNK1 , MUSK, TOPK , and TNIK (IC 50 =1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC 50 =3.46-5.27 μM for PI3K α/β/γ/K/δ). In Vitro Orobol binds to CK1ε in an ATP-competitive manner and exerts anti-obesity effects by targeting casein kinase 1 epsilon. Orobol (5-20 μM) effectively suppresses MDI (isobutylmethylxanthine, dexamethasone and insulin (MDI))-induced phosphorylation of 4E-BP1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Orobol attenuates high fat diet-induced weight gain and lipid accumulation without affecting food intake in C57BL/6J mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: HFD-induced obesity in C57BL/6J miceDosage: 10 mg/kg Administration: Intragastrically; daily for 23 weeks Result: Significantly reduced body weight by 17.3% compared to the HFD group. Form:Solid